Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19929566 | 0.94 | HPGD (0.52) | ALBLMNAPKMHPGDTSHR | |
| SCHEMBL24253210 | 0.89 | ALB (0.57) | ALBLMNAPKMHPGDTSHR | |
| SCHEMBL19929568 | 0.88 | ALB (0.43) | ALBLMNAPKMHPGDALDH1A1 | |
| SCHEMBL26241596 | 0.88 | ALB (0.71) | ALBLMNAPKMHPGDTSHR | |
| SCHEMBL24253212 | 0.88 | ALB (0.71) | ALBLMNAPKMHPGDTSHR | |
| SCHEMBL19929574 | 0.88 | ALB (0.56) | ALBLMNAPKMHPGDTSHR | |
| SCHEMBL24253209 | 0.88 | ALB (0.56) | ALBLMNAPKMHPGDTSHR | |
| SCHEMBL19929570 | 0.88 | ALB (0.56) | ALBLMNAPKMHPGDTSHR | |
| SCHEMBL24253213 | 0.85 | POLB (0.62) | ALBLMNAPKMALDH1A1KMT2A | |
| SCHEMBL19929575 | 0.85 | ALB (0.53) | ALBLMNAPKMTSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230332199-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20180066298-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | RATIO THERAPEUTICS, INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230332199-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | IL1RN, IL2RA, IL1A | ALB 31/4885LMNA 2979/4885PKM 4669/4885 |
| US-20180066298-A1 | FUNCTIONALLY MODIFIED POLYPEPTIDES AND RADIOBIOSYNTHESIS | IL1RN, IL2RA, IL1A | ALB 31/4885LMNA 2979/4885PKM 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.